Online citations, reference lists, and bibliographies.
← Back to Search

A Rating Scale For Drug-induced Akathisia.

T. Barnes
Published 1989 · Psychology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
A rating scale for drug-induced akathisia has been derived that incorporates diagnostic criteria for pseudoakathisia, and mild, moderate, and severe akathisia. It comprises items for rating the observable, restless movements which characterise the condition, the subjective awareness of restlessness, and any distress associated with the akathisia. In addition, there is an item for rating global severity. A standard examination procedure is recommended. The inter-rater reliability for the scale items (Cohen's kappa) ranged from 0.738 to 0.955. Akathisia was found in eight of 42 schizophrenic in-patients, and nine had pseudoakathisia, where the typical sense of inner restlessness was not reported.
This paper references
Sponta neous and drug-induced movement disorders Akathisia variants and tardive dyskinesia (letter)
C D Marsden (1015)
Le traitment de la maladie de Parkinson et des manifestations extra pyramidales par Ic diethylaminoethyl n-thiodiphenylamine (2987 RP): resultatsd'une anee d'application
J Sigwald (1947)
Le syndrome extrapyramidal et diencephalique au cours des traitements au Largactil et au Serpasil
H. STECK (1954)
Extrapyramidal Symptoms and Other Side Effects of Trifluoperazine. Clinicaland PharmacologicalAspects. Philadelphia: Lea and Febiger
Freyhan (1958)
10.1111/J.0954-6820.1961.TB00286.X
Comparison between akathisia developing on treatment with phenothiazine derivatives and the restless legs syndrome.
S. Blom (1961)
10.1001/JAMA.1961.03040120016004
A survey of drug-induced extrapyramidal reactions.
F. Ayd (1961)
10.1111/j.1600-0447.1970.tb02066.x
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
G. Simpson (1970)
10.1001/ARCHPSYC.1974.01760130049008
Why do schizophrenic patients refuse to take their drugs
T. Putten (1974)
Why do schizophrenic patients refuse to take their drugs?
T. van Putten (1974)
10.1016/0010-440x(75)90019-x
The many faces of akathisia.
T. van Putten (1975)
10.1016/0010-440X(75)90019-X
The many faces of akathisia.
T. Putten (1975)
10.1192/BJP.128.2.156
The Leeds scales for the self-assessment of anxiety and depression.
R. Snaith (1976)
10.1001/JAMA.1978.03290200063026
Neuroleptics. Violence as a manifestation of akathisia.
W. Keckich (1978)
10.1176/AJP.136.8.1088
An unusual case of akathisia.
B. Kumar (1979)
10.1176/AJP.139.3.372
Perception of tardive dyskinesia in outpatients receiving maintenance neuroleptics.
A. Rosen (1982)
10.1016/0010-440X(82)90084-0
Akathisia, pseudoakathisia and tardive dyskinesia: clinical examples.
M. Munetz (1982)
Akathisia, pseudoakathisia and tardive dyskinesia
(1982)
10.1192/BJP.143.2.139
Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions.
W. Braude (1983)
10.1017/S003329170005008X
Tardive dyskinesia: a 3-year follow-up study.
T. Barnes (1983)
10.1097/00004714-198308000-00006
Suicide associated with akathisia and depot fluphenazine treatment.
M. Shear (1983)
Tardive dyskinesia : a three year follow - up study
W. M. BRAUDE (1983)
10.1001/ARCHPSYC.1983.01790220026004
Akathisia with haloperidol and thiothixene.
T. van Putten (1984)
10.1001/ARCHPSYC.1985.01790320087012
Akathisia and tardive dyskinesia. Changing concepts.
S. Stahl (1985)
10.1176/AJP.142.4.499
Suicide attempts associated with akathisia.
R. Drake (1985)
Homicide and Suicide Associated With Akathisia and Haloperidol
J. Schulte (1985)
10.1001/ARCHPSYC.1985.01790320042006
Akathisia variants and tardive dyskinesia.
T. Barnes (1985)
Sponta neous and drug - induced movement disorders
D. Blumer (1985)
Akathisia and tardive dyskinesia
F M Stahl (1985)
10.1097/00004714-198606000-00024
A case of suicidal and homicidal ideation and akathisia in a double-blind neuroleptic crossover study.
E. Shaw (1986)
10.1001/ARCHPSYC.1986.01800100109017
Akathisia variants and tardive dyskinesia.
M. Munetz (1986)
10.1001/ARCHPSYC.1986.01800100109019
Toward a more reliable diagnosis of akathisia.
T. van Putten (1986)
10.1001/ARCHPSYC.1986.01800100109018
Akathisia Variants and Tardive Dyskinesia-Reply
S. Stahl (1986)
10.1136/jnnp.49.8.861
The clinical phenomenon of akathisia.
W. Gibb (1986)
Akathisia and antipsychotic drugs (editorial)
(1986)
Akathisia and antipsychotic drugs ( editorial )
C. D. MARSDEN (1986)
Effect of clorazepate on depressed mood in anxious patients.
Zung Ww (1987)
The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
Barnes Tr (1987)
10.1176/AJP.144.9.1148
Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study.
P. Weiden (1987)
The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
T. Barnes (1987)
Charing Cross and Westminster Medical School, London SW1P 2AR
N. Robinson (1988)
A scale for rating drug - induced akathisia ( abstract : Bi - EnnialWhiter Workshop on Schiwphrenia , Badgastein , Austria , January 1988 )
S. BLOM (1988)
Behavioral Toxicity of Antipsychotic Drugs ' l ' heodore
Van Putten
BARNES
H@.s, 0., et a! (1987) Clinical non-recognition of neuroleptic-induced movement disorders: a cautionary study
P Walden



This paper is referenced by
10.1093/schbul/sbab002
A Network of Psychopathological, Cognitive, and Motor Symptoms in Schizophrenia Spectrum Disorders.
B. Moura (2021)
10.1016/j.jpsychires.2021.05.018
Different trajectories of neurological soft signs progression between treatment-responsive and treatment-resistant schizophrenia patients.
S. S. Lui (2021)
10.1016/j.schres.2020.12.006
Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
C. Correll (2021)
10.3389/fpsyt.2021.679021
Psychopathological Symptom Load and Distinguishable Cerebral Blood Flow Velocity Patterns in Patients With Schizophrenia and Healthy Controls: A Functional Transcranial Doppler Study
S. Egger (2021)
10.3389/fpsyt.2021.728265
Case Report: Changes in Regional Cerebral Blood Flow in Chronic Akathisia of a Depressed Patient Before and After Electroconvulsive Therapy Treatment
Akihito Suzuki (2021)
10.1016/j.schres.2021.06.007
Internalized stigma among people with schizophrenia: Relationship with socio-demographic, clinical and medication-related features
S. Barlati (2021)
10.1016/j.psychres.2020.113528
Stability of Verbal Fluency in Outpatients with Schizophrenia
K. Grimes (2021)
10.4102/sajpsychiatry.v27i0.1527
Characteristics and outcomes of patients admitted to the first psychiatric intensive care unit in Egypt
T. Okasha (2021)
10.3389/fpsyt.2021.660850
Increased Glutamate Plus Glutamine in the Right Middle Cingulate in Early Schizophrenia but Not in Bipolar Psychosis: A Whole Brain 1H-MRS Study
J. Bustillo (2021)
10.1016/j.pnpbp.2021.110275
Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort
P. S. D. Verville (2021)
10.3389/fpsyg.2021.568286
Measurement of Motivation States for Physical Activity and Sedentary Behavior: Development and Validation of the CRAVE Scale
M. Stults-Kolehmainen (2021)
10.1016/j.rpsm.2021.01.004
Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3).
J. M. Son (2021)
10.3389/fpsyt.2021.702720
Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese
Qi Zhang (2021)
10.1136/bmjopen-2020-044656
Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial
T. Butler (2021)
10.3389/fpsyt.2021.681418
Safety and Efficacy of High-Dose Vitamin B6 as an Adjunctive Treatment for Antipsychotic-Induced Hyperprolactinemia in Male Patients With Treatment-Resistant Schizophrenia
C. Zhuo (2021)
10.2147/NDT.S301225
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
Á. Barabássy (2021)
10.1097/JCP.0000000000001324
Nanocurcumin as an Add-on to Antipsychotic Drugs for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia
Masumeh Hosseininasab (2021)
10.9758/cpn.2021.19.1.117
Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics
Seung-Gul Kang (2021)
10.1016/j.euroneuro.2021.02.009
Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial
M. Gómez-Revuelta (2021)
10.1186/s12888-021-03437-2
Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial
Sylvie Beumer (2021)
10.2147/NDT.S283395
Comparative Study of the Effects of Atypical Antipsychotic Drugs on Plasma and Urine Biomarkers of Oxidative Stress in Schizophrenic Patients
A. Dietrich-Muszalska (2021)
10.1192/bjp.2020.225
Towards safer risperidone prescribing in Alzheimer's disease
S. Reeves (2021)
10.1192/bjo.2021.945
Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophrenia
Yi Su (2021)
10.1093/schbul/sbab010
Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial
I. Sommer (2021)
10.3389/fpsyt.2021.694394
The Impact of THC and CBD in Schizophrenia: A Systematic Review
Saeed Ahmed (2021)
10.1016/j.schres.2021.04.009
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
R. Kahn (2021)
10.1371/journal.pone.0257129
Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies
Tilahun Ali (2021)
10.1192/bjo.2021.1005
Patient, family and provider views of measurement-based care in an early-psychosis intervention programme
Ari B. Cuperfain (2021)
10.1007/978-3-030-62113-1_14
First-Episode & Early Psychosis in Transition-Age Youth
Pari Faraji (2021)
10.3389/fpsyt.2021.643112
Prospective Long-Term Cohort Study of Subjects With First-Episode Psychosis Examining Eight Major Outcome Domains and Their Predictors: Study Protocol
V. Peralta (2021)
10.1016/j.jad.2021.03.076
Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression.
L. Citrome (2021)
10.9758/cpn.2021.19.2.355
Effect of Varenicline on Tardive Dyskinesia: A Pilot Study
S. Caroff (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar